financetom
Business
financetom
/
Business
/
Ispire Technology Closes $12.3 Million Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ispire Technology Closes $12.3 Million Offering
Mar 27, 2024 2:59 AM

05:34 AM EDT, 03/27/2024 (MT Newswires) -- Ispire Technology ( ISPR ) said late Tuesday it has closed its offering of about 2.1 million common shares priced at $6 apiece for gross proceeds of $12.3 million.

Roth Capital Partners served as the lead placement agent for the offering, while TFI Securities and Futures Limited served as co-placement agent.

Price: 5.89, Change: -0.04, Percent Change: -0.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Connected fitness platform Peloton beats Q1 revenue estimates
Connected fitness platform Peloton beats Q1 revenue estimates
Nov 6, 2025
Overview * Peloton Q1 FY2026 revenue falls 6% yr/yr but beats guidance * Net income rises to $14 mln, up $15 mln yr/yr * Adjusted EBITDA increases 2% yr/yr, $18 mln above guidance Outlook * Peloton expects Q2 revenue between $665 mln and $685 mln * Company projects Q2 gross margin at approximately 49.0% * Peloton forecasts full-year revenue of...
Lineage Cell Therapeutics' Q3 net loss widens, driven by warrant liabilities
Lineage Cell Therapeutics' Q3 net loss widens, driven by warrant liabilities
Nov 6, 2025
Overview * Lineage Q3 revenue decreased to $3.7 mln from $3.8 mln in 2024 * Net loss for Q3 increased to $29.75 mln, driven by warrant liabilities Outlook * Lineage plans to drive milestone revenue from Roche and Genentech alliance * Lineage aims to capitalize on investments in cell transplant platform Result Drivers * COLLABORATION WITH WDI - Lineage entered...
Intellia Q3 net loss narrows
Intellia Q3 net loss narrows
Nov 6, 2025
Overview * Intellia Q3 net loss narrows to $101.3 mln, collaboration revenue rises * FDA places clinical hold on MAGNITUDE trials due to safety concerns * Enrollment completed in Phase 3 HAELO trial, topline data expected mid-2026 Outlook * Company suspends milestone guidance for nex-z pending regulatory alignment * Intellia expects lonvo-z topline data by mid-2026 * Company anticipates U.S....
Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries
Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries
Nov 6, 2025
Overview * SIGA ( SIGA ) Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year * Company attributes revenue decline to lower product sales, especially TPOXX deliveries * SIGA ( SIGA ) focuses on securing new procurement contracts for future revenue growth Outlook * SIGA ( SIGA )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved